Day 3 – 23 September 2021
|
Interactive poster session 5 Clinicopathological prognostic stratification for renal survival in the Japanese IgA nephropathy prospective cohort study (J-IGACS) Clinicopathological features, risk factors, and outcomes of immunoglobulin A nephropathy associated with hepatitis B virus infection Long-term outcomes of IgA nephropathy patients with less than 25% crescents and mild proteinuria FcαRI-mediated neutrophil activation contributed to the pathogenesis of IgA vasculitis with nephritis WITHDRAWN The Comparison of Efficacy and Safety in High-Risk IgA Nephropathy with Low-dose and Full-dose Prednisone Treatment ---A Prospective Randomized Controlled Trial |
|
| 09:00–09:05 | Break |
| Industry Symposium 5 | |
| 10:05–10:15 | Coffee Break |
| 10:15–11:05 |
Plenary Session 9 What progress has been made in understanding IgAN in children in the last decade? The challenges of designing a clinical trial in paediatric kidney disease What can CureGN tell us about IgAN in children and young adults? |
| 11:05–11:10 | Break |
| 11:10–12:00 |
Plenary Session 10 IgAN: A South-Asian Perspective A South American Perspective Establishing a global network to promote involvement in kidney disease research |
| 12:00–12:25 | Lunch Break |
| 12:25–13:25 |
Free Communications 3 Selective ETA Antagonist Atrasentan, Rapidly Reduces Albuminuria and Downregulates Intra-renal Pro-Inflammatory and Pro-Fibrotic Transcriptional Networks in the gddY Mouse Model of Spontaneous IgA Nephropathy Analysis of the effect of TRF-budesonide (Nefecon) on urinary sCD163 in patients with IgAN from the Phase 2 NEFIGAN trial Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VIS649, an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers: Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study Impact of polyclonal anti-T-lymphocyte immunoglobulins on the recurrence of IgA nephropathy after kidney transplantation: The pirat study BAFF-dependent IgA production do not play a pivotal role in the pathogenesis of murine IgA nephropathy |
| 13:25–13:30 | Break |
| 13:30–14:30 |
Panel Discussion 3 Panel members: Ali Gharavi (United States), Renato Monteiro (France), Julio Saez-Rodrigo (Germany), Lesley Inker (United States |
| 14:30–14:35 | Break |
| 14:35–15:35 | Industry Symposium 5 |
| 15:35–15:40 | Break |
| 15:40–16:00 | Awards |
| 16:00–16:15 | Final word & introduction of next symposium |
|
All times in the symposium programme are in Central European Summer Time – CEST (UTC + 2). |
|
